Dominik Steubl

Also affiliated with TUM Klinikum

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials”.

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

Diabetes Care(2022)10.2337/dc21-2034

N/A

1.4DataRank · unranked

44 citations

Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J. Hauske +6 more

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD

Journal of the American Society of Nephrology(2023)10.1681/asn.0000000000000271

N/A

1.4DataRank · unranked

45 citations

Natalie Staplin, David Keane, Christoph Wanner, Susanne Brenner, Vladimir Cejka +25 more

Genetic and Clinical Predictors of Age of ESKD in Individuals With Autosomal Dominant Tubulointerstitial Kidney Disease Due to UMOD Mutations

Kidney International Reports(2020)10.1016/j.ekir.2020.06.029

N/A

0DataRank · unranked

54 citations

Petr Vyleťal, Céline Schaeffer, Eric Olinger, Martina Živná, Kateřina Hodaňová +37 more

Genome-wide studies reveal factors associated with circulating uromodulin and its relationships to complex diseases

JCI Insight(2022)10.1172/jci.insight.157035

N/A

0DataRank · unranked

23 citations

Yurong Cheng, Francesco Consolato, Guglielmo Schiano, Michael Chong, Maik Pietzner +38 more

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY

American Journal of Kidney Diseases(2025)10.1053/j.ajkd.2025.10.004

N/A

0DataRank · unranked

8 citations

Rebecca J. Sardell, Natalie Staplin, Olivier Devuyst, Daniel S. Chapman, Michael Hill +21 more

Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction

Nature Cardiovascular Research(2025)10.1038/s44161-025-00657-7

N/A

0DataRank · unranked

3 citations

Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker, Josephine Harrington, W. Schuyler Jones +8 more